GlassScriptPhysician profile
Melissa Brownlow
NPI 1205350766
$20,186.31
in general payments reported to CMS, 2019-2025
37 companies · $4,659 in 2025
The $4,659 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,370 · 2022: $3,759 · 2023: $5,049 · 2024: $4,348 · 2025: $4,659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $18.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,038.50 |
| Education | $18.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,370.31 | 2021-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $2,321.46 | 2021-2025 | |
| Janssen Biotech, INC. | $2,158.90 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $1,381.37 | 2021-2025 | Cimzia, Bimzelx |
| Ani Pharmaceuticals, INC. | $1,079.97 | 2022-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $1,063.69 | 2021-2025 | Benlysta |
| Lilly USA, LLC | $1,010.87 | 2021-2025 | Taltz, Zepbound, Olumiant |
| Novartis Pharmaceuticals Corporation | $972.33 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $831.81 | 2021-2025 | Saphnelo, Evusheld |
| Mallinckrodt Hospital Products INC. | $764.42 | 2021-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $733.13 | 2021-2025 | Ofev, Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $720.46 | 2022-2025 | Orencia |
| Pfizer INC. | $650.55 | 2021-2025 | |
| Horizon Therapeutics Plc | $503.31 | 2021-2023 | Krystexxa |
| Organon LLC | $483.50 | 2021-2025 | Hadlima, Renflexis, Ontruzant |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $374.35 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $263.86 | 2021-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $255.09 | 2021-2025 | Strensiq |
| Actelion Pharmaceuticals US, INC. | $171.64 | 2021-2025 | Opsumit, Uptravi |
| Genentech USA, INC. | $124.15 | 2021-2024 | Actemra, Rituxan |
| Radius Health, INC. | $102.67 | 2024-2025 | Tymlos |
| Fresenius Kabi USA, LLC | $93.04 | 2023-2025 | Idacio |
| Bioventus LLC | $92.99 | 2021-2023 | Durolane |
| Sandoz INC. | $88.52 | 2022-2025 | Hyrimoz |
| Kiniksa Pharmaceuticals International, Plc | $82.20 | 2024 | Arcalyst |
| Sobi, INC | $77.94 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $67.34 | 2025 | Tremfya |
| Celgene Corporation | $63.54 | 2024 | Orencia |
| Scilex Pharmaceuticals INC. | $62.37 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $49.77 | 2021-2023 | |
| Invivyd INC | $41.51 | 2025 | Pemgarda |
| Boston Scientific Corporation | $33.69 | 2025 | Spectra Wavewriter |
| Abbott Laboratories | $25.56 | 2021 | |
| Tersera Therapeutics LLC | $21.64 | 2022 | |
| Celltrion USA INC. | $18.16 | 2023 | Yuflyma |
| Mylan Institutional INC. | $15.12 | 2023 | Hulio |
| Avanos Medical | $15.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Brownlow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.